Table 4.
Sensitivity and specificity of clinical and risk scores to identify individuals with subclinical atherosclerosisa
| Framingham Risk Scored | Metabolic Syndromee | Cardiovascular Health Indexf | |||
|---|---|---|---|---|---|
| Intermediate Risk | High Risk | Yes | Average | Inadequate | |
| Sensitivityb | 33.9% (33.8─33.9) |
26.6% (26.5─26.6) |
36.7% (36.6─36.7) |
94.8% (94.7─94.8) |
78.0% (77.8─78.1) |
| Specificityc | 64.9% (64.8─64.9) |
87.4% (87.3─87.4) |
75.3% (75.2─75.3) |
14.9% (14.8─14.9) |
53.2% (53.1─53.3) |
aProportion estimates of the eligible population after applying sampling weights to the study sample (% (95% CI))
bSensitivity: probability of correctly detecting true positive results (individuals who do have subclinical atherosclerosis)
cSpecificity: probability of correctly detecting true negative results (individuals who do not have subclinical atherosclerosis)
dFramingham Risk Score: Intermediate (10–20% 10-year risk) or high risk (> 20% 10-year risk) vs. low risk (referent value; < 10% 10-year risk)
eMetabolic syndrome: Presence of metabolic syndrome (3 or more risk factors) vs. no metabolic syndrome (referent value; < 3 risk factors)
fCardiovascular Health Index (CVHI): Average CV health (5–9 total points) or inadequate CV health (0–4 total points) vs. optimum CV health (reference value; 10–14 total points)